Physician profile
John K Sowell
NPI 1851376263
$3,937.90
in general payments reported to CMS, 2019-2025
29 companies · $654 in 2025
The $654 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $218 · 2021: $39.84 · 2022: $636 · 2023: $858 · 2024: $639 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $805.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $387.99 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $330.81 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $304.76 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $270.77 | 2020-2024 | Tremfya |
| Abbvie INC. | $246.61 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $242.51 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Csl Behring | $213.86 | 2019-2020 | |
| Genzyme Corporation | $187.43 | 2019-2025 | |
| Ucb, INC. | $162.14 | 2019-2023 | Bimzelx |
| Lilly USA, LLC | $129.90 | 2019-2023 | Taltz |
| Galderma Laboratories, L.P. | $99.74 | 2019-2025 | Aklief, Epsolay, Nemluvio |
| Amgen INC. | $93.02 | 2019-2025 | Otezla, Otezla |
| Genentech USA, INC. | $70.48 | 2019-2020 | |
| Pfizer INC. | $64.55 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $56.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.09 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.73 | 2019-2022 | |
| Allergan, INC. | $25.05 | 2019-2020 | |
| Mylan Institutional INC. | $22.47 | 2023 | Hulio |
| Shire North American Group INC | $20.06 | 2019 | |
| Kerecis Limited | $17.13 | 2022 | |
| Epi Health, LLC | $15.40 | 2020 | |
| Organon LLC | $15.20 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $14.79 | 2023 | Ycanth |
| Dermavant Sciences, INC. | $13.81 | 2023 | Vtama |
| Optinose US, INC. | $13.67 | 2020 | |
| Mayne Pharma Commercial LLC | $12.83 | 2019 | |
| Almirall LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.